Clinical Trials
The Nerivio REN Wearable Was Evaluated in Nine Clinical Studies
The first study was a prospective, double-blind, randomized, crossover, sham-controlled pilot study. The second study was a multi-center, prospective, randomized, double-blind, sham-controlled pivotal study that evaluated the safety and efficacy of the Nerivio device in patients with episodic migraines.The other two studies were prospective, open label studies that evaluated the safety and efficacy of the Nerivio device in patients with chronic migraines (>15 headache days/month) The fifth study was a prospective, open label studies that evaluated the safety and efficacy of the Nerivio device in adolescence patients (aged 12-17). The six study was a prospective, double-blind, randomized, crossover, sham-controlled study that evaluated the safety and efficacy of the Nerivio device as a migraine preventive therapy.
The seventh study was a prospective, single arm, open label post market study assessing the safety and efficacy of the Nerivio device for the treatment of migraine in children under the age of 12. The eighth study was a Real-World Evidence (RWE) data analysis of 1-year consecutive use of the Nerivio device, and the nineth study was a retrospective controlled survey study to assess the safety of treating migraine with Nerivio during pregnancy and 3 Months postpartum.
The first study was a prospective, double-blind, randomized, crossover, sham-controlled pilot study. The second study was a multi-center, prospective, randomized, double-blind, sham-controlled pivotal study that evaluated the safety and efficacy of the Nerivio device in patients with episodic migraines.The other two studies were prospective, open label studies that evaluated the safety and efficacy of the Nerivio device in patients with chronic migraines (>15 headache days/month) The fifth study was a prospective, open label studies that evaluated the safety and efficacy of the Nerivio device in adolescence patients (aged 12-17). The six study was a prospective, double-blind, randomized, crossover, sham-controlled study that evaluated the safety and efficacy of the Nerivio device as a migraine preventive therapy.
The seventh study was a prospective, single arm, open label post market study assessing the safety and efficacy of the Nerivio device for the treatment of migraine in children under the age of 12. The eighth study was a Real-World Evidence (RWE) data analysis of 1-year consecutive use of the Nerivio device, and the nineth study was a retrospective controlled survey study to assess the safety of treating migraine with Nerivio during pregnancy and 3 Months postpartum.